Loading...
XSHE300255
Market cap2.49bUSD
Jan 16, Last price  
19.83CNY
1D
4.87%
1Q
8.72%
Jan 2017
151.01%
IPO
374.40%
Name

Hebei Changshan Biochemical Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:300255 chart
P/E
—
P/S
12.92
EPS
—
Div Yield, %
0.59%
Shrs. gr., 5y
-0.31%
Rev. gr., 5y
-3.12%
Revenues
1.41b
-39.63%
110,840,402253,753,457466,717,967423,479,330575,558,108704,542,401811,284,570915,987,2291,118,414,4311,420,161,4481,652,633,9212,071,479,8092,363,785,8552,968,050,8422,336,229,8381,410,439,649
Net income
-1.24b
L
9,283,26936,365,48660,190,52670,799,65699,088,101115,182,918133,732,534156,297,275175,487,223196,919,210139,987,092225,285,377252,842,315233,573,84017,513,464-1,240,210,953
CFO
34m
+979.06%
024,210,52129,245,67417,041,5330000171,959,738162,275,728292,806,829002,871,4983,125,50333,725,979
Dividend
Jun 27, 20230.005 CNY/sh

Profile

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of crude heparin, heparin raw materials, and heparin preparations for the treatment of cardiovascular and cerebrovascular diseases in China. Its products include crude heparin sodium, heparin sodium raw materials, heparin sodium injections, low molecular weight heparin calcium raw materials and injections, enoxaparin sodium raw materials and injections, nadra Heparin calcium raw materials, nadroparin calcium injections, and dalteparin sodium raw materials and injections. The company was founded in 2000 and is based in Shijiazhuang, China.
URL
http://www.hbcsbio.com/
IPO date
Aug 19, 2011
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,410,440
-39.63%
2,336,230
-21.29%
Cost of revenue
2,416,475
2,115,147
Unusual Expense (Income)
NOPBT
(1,006,036)
221,083
NOPBT Margin
9.46%
Operating Taxes
16,459
7,960
Tax Rate
3.60%
NOPAT
(1,022,495)
213,123
Net income
(1,240,211)
-7,181.47%
17,513
-92.50%
Dividends
(107,732)
Dividend yield
0.90%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
1,513,573
1,322,912
Long-term debt
814,274
1,128,843
Deferred revenue
62,476
64,800
Other long-term liabilities
1
Net debt
2,092,347
1,647,014
Cash flow
Cash from operating activities
33,726
3,126
CAPEX
(239,324)
Cash from investing activities
(238,847)
Cash from financing activities
(294,945)
653,444
FCF
(215,155)
(215,024)
Balance
Cash
230,923
797,797
Long term investments
4,577
6,944
Excess cash
164,978
687,929
Stockholders' equity
1,203,414
2,651,215
Invested Capital
4,023,779
4,855,784
ROIC
4.61%
ROCE
3.99%
EV
Common stock shares outstanding
918,675
919,061
Price
13.01
137.41%
5.48
-32.60%
Market cap
11,951,959
137.31%
5,036,454
-32.60%
EV
14,044,306
6,683,468
EBITDA
(930,648)
278,019
EV/EBITDA
24.04
Interest
99,540
93,043
Interest/NOPBT
42.09%